Mazdutide: First Approval

Oct 1, 2025Drugs

Mazdutide: First Official Approval

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Mazdutide received its first approval in June 2025 for long-term body weight management in adults with a BMI of ≥ 28 kg/m².

Mazdutide acts as a dual agonist for both glucagon and GLP-1 receptors.
It is being developed for weight management in adults with obesity or overweight.
The drug is also approved for glycaemic control in adults with type 2 diabetes.
Mazdutide is under evaluation for additional conditions such as fatty liver disease and obstructive sleep apnoea.

AI simplified

Mazdutide (Xinermei) is a dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Eli Lilly and Company along with Innovent Biologics for use in weight management in adults with obesity or overweight and for the treatment of type 2 diabetes (T2D). In June 2025, mazdutide received its first approval, in China, for use (in combination with diet control and increased physical activity) in long-term body weight management in adults with a body-mass index (BMI) of ≥ 28 kg/mor with a BMI ≥ 24 kg/mtogether with one or more weight-related comorbidity. Subsequently, in September 2025, mazdutide also received approval in China for use in glycaemic control in adults with T2D. Additionally, mazdutide is under clinical evaluation for use in the treatment of metabolic dysfunction-associated fatty liver disease, obstructive sleep apnoea and alcohol use disorder. This article summarises the milestones in the development of mazdutide leading to this first approval for long-term body weight management in adults with obesity or overweight. ® 2 2